Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-20 |
2024-03 |
-0.4 |
N/A |
N/A |
N/A |
2024-03-12 |
2023-12 |
-0.41 |
-0.41 |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.44 |
-0.4 |
0.04 |
9.09% |
2023-11-09 |
2023-09 |
-0.44 |
N/A |
N/A |
N/A |
2023-08-10 |
2023-06 |
-0.48 |
-0.44 |
0.04 |
8.33% |
2023-08-10 |
2023-06 |
-0.48 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-21 |
Wedbush |
Upgrade |
|
Outperform |
2023-08-09 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-06 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-23 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-15 |
Credit Suisse |
Upgrade |
Outperform |
Outperform |
2023-03-16 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-03-29 |
ATLAS VENTURE FUND X, L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2021-12-13 |
ATLAS VENTURE FUND XI L.P |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2023-08-03 |
BONITA DAVID P |
Director |
0.00 |
Stock Award(Grant) |
2021-12-13 |
FORMELA JEAN FRANCOIS |
Director |
0.00 |
Sale |
2023-08-03 |
ORBIMED ADVISORS, L.L.C. |
Unknown |
0.00 |
Stock Award(Grant) |
2021-03-29 |
STAMPACCHIA OTELLO |
Director |
0.00 |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Orbimed Advisors LLC. |
9.40M |
61.67M |
25.09% |
2023-06-29 |
FMR, LLC |
5.07M |
33.26M |
13.53% |
2023-06-29 |
Atlas Venture Life Science Advisors, LLC |
5.02M |
32.92M |
13.39% |
2023-06-29 |
BVF Inc. |
3.17M |
20.79M |
8.46% |
2023-06-29 |
Omega Fund Management, Llc |
2.25M |
14.75M |
6.00% |
2023-06-29 |
Chi Advisors Llc |
2.12M |
13.92M |
5.66% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-07-30 |
Fidelity Advisor Biotechnology Fund |
1.54M |
7.94M |
4.11% |
2023-07-30 |
Fidelity Small Cap Growth Fund |
1.07M |
5.51M |
2.86% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
654.66K |
4.29M |
1.75% |
2023-07-30 |
Fidelity Series Small Cap Opportunities Fund |
583.82K |
3.01M |
1.56% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
539.63K |
2.50M |
1.44% |
2023-08-30 |
iShares Russell 2000 ETF |
427.88K |
1.99M |
1.14% |